Selected highlights from the American Academy of Neurology annual meeting, Seattle WA, 2-7 April 2022.
April 6 Edition
April 4 Edition
COVID-19 boosters
MS and pregnancy
First CBT trial for MS fatigue
Clinical practice Read More
Neurology
AAN 2022 HIGHLIGHTS – MONDAY, APRIL 4 EDITION
April 4, 2022Selected highlights from the American Academy of Neurology annual meeting, Seattle WA, 2-7 April 2022.
April 6 Edition
April 5 Edition
DMTs and vaccine response
Age and outcomes
Biomarkers
Radiologically isolated syndrome (RIS)
Clinical practice Read More
Ofatumumab safety update: modest effect on Ig
March 25, 2022Ofatumumab, an anti-CD20 MAb administered subcutaneously, appears to have only modest effects on serum immunoglobulins, according to an updated safety analysis from recent clinical trials (Hauser et al. Mult Scler 2022; epublished March 1, 2022). A preliminary analysis of the data was published at last year’s ECTRIMS (Wiendl et al. ECTRIMS 2021;P931) (see also ECTRIMS 2021 slide deck, NeuroSens, October 21, 2021). Read More
Can COVID vaccination cause demyelination?
March 7, 2022At the 2022 ACTRIMS Forum, three groups presented data on acute demyelinating events following COVID-19 vaccination. Read More
ACTRIMS Forum 2022 – Update on anti-CD20s and vaccine response
March 1, 2022SPECIAL REPORT
Several studies presented at the ACTRIMS Forum 2022 provided some additional details on the COVID-19 vaccine response among MS patients treated with anti-CD20 therapies. The data suggest that vaccine response may differ somewhat among anti-CD20 agents, which may be related to the depth and/or duration of B cell suppression, the timing of vaccination and patient factors such as age. Read More